Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: PHGDH

Gene summary for PHGDH

Gene summary.

Gene information	Species	Human
	Gene symbol	PHGDH
	Gene ID	26227
	Gene name	phosphoglycerate dehydrogenase
	Gene Alias	3-PGDH
	Cytomap	1p12
	Gene Type	protein-coding
	GO ID	GO:0006082
	UniProtAcc	O43175

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
26227	PHGDH	GSM4909282	Human	Breast	IDC	3.63e-29	7.08e-01	-0.0288
26227	PHGDH	GSM4909285	Human	Breast	IDC	5.60e-59	9.13e-01	0.21
26227	PHGDH	GSM4909287	Human	Breast	IDC	2.74e-05	3.58e-01	0.2057
26227	PHGDH	GSM4909293	Human	Breast	IDC	1.44e-06	-2.18e-01	0.1581
26227	PHGDH	GSM4909297	Human	Breast	IDC	2.37e-06	-2.15e-01	0.1517
26227	PHGDH	GSM4909301	Human	Breast	IDC	9.06e-08	-2.20e-01	0.1577
26227	PHGDH	GSM4909302	Human	Breast	IDC	1.51e-08	-2.48e-01	0.1545
26227	PHGDH	GSM4909311	Human	Breast	IDC	1.09e-06	-1.26e-01	0.1534
26227	PHGDH	GSM4909312	Human	Breast	IDC	9.13e-03	-1.53e-01	0.1552
26227	PHGDH	GSM4909316	Human	Breast	IDC	1.10e-02	4.01e-01	0.21
26227	PHGDH	GSM4909319	Human	Breast	IDC	3.30e-12	-2.38e-01	0.1563
26227	PHGDH	GSM4909321	Human	Breast	IDC	3.79e-06	-1.68e-01	0.1559
26227	PHGDH	M2	Human	Breast	IDC	5.22e-03	4.14e-01	0.21
26227	PHGDH	NCCBC5	Human	Breast	DCIS	3.27e-04	-9.15e-02	0.2046
26227	PHGDH	P1	Human	Breast	IDC	5.70e-03	-1.17e-01	0.1527
26227	PHGDH	P2	Human	Breast	IDC	4.44e-04	3.81e-01	0.21
26227	PHGDH	DCIS2	Human	Breast	DCIS	1.23e-34	1.30e-01	0.0085
26227	PHGDH	LZE7T	Human	Esophagus	ESCC	4.41e-04	5.14e-01	0.0667
26227	PHGDH	LZE24T	Human	Esophagus	ESCC	1.50e-11	7.41e-01	0.0596
26227	PHGDH	LZE21T	Human	Esophagus	ESCC	2.54e-03	4.34e-01	0.0655

Page: 1 2 3 4 5 6

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:004639421	Liver	HCC	carboxylic acid biosynthetic process	198/7958	314/18723	1.19e-13	6.78e-12	198
GO:00086522	Liver	HCC	cellular amino acid biosynthetic process	58/7958	76/18723	1.98e-09	5.63e-08	58
GO:19016052	Liver	HCC	alpha-amino acid metabolic process	124/7958	195/18723	2.07e-09	5.79e-08	124
GO:19016072	Liver	HCC	alpha-amino acid biosynthetic process	53/7958	68/18723	2.62e-09	7.16e-08	53
GO:00065202	Liver	HCC	cellular amino acid metabolic process	167/7958	284/18723	1.91e-08	4.56e-07	167
GO:00090692	Liver	HCC	serine family amino acid metabolic process	29/7958	40/18723	1.17e-04	9.87e-04	29
GO:00090662	Liver	HCC	aspartate family amino acid metabolic process	34/7958	49/18723	1.28e-04	1.06e-03	34
GO:0009064	Liver	HCC	glutamine family amino acid metabolic process	47/7958	78/18723	1.17e-03	6.54e-03	47
GO:00219154	Liver	HCC	neural tube development	82/7958	152/18723	2.83e-03	1.33e-02	82
GO:00420631	Liver	HCC	gliogenesis	148/7958	301/18723	1.10e-02	4.07e-02	148
GO:002290018	Oral cavity	OSCC	electron transport chain	126/7305	175/18723	6.65e-19	8.42e-17	126
GO:000609118	Oral cavity	OSCC	generation of precursor metabolites and energy	286/7305	490/18723	1.45e-18	1.71e-16	286
GO:00420635	Oral cavity	OSCC	gliogenesis	154/7305	301/18723	1.10e-05	1.14e-04	154
GO:00067905	Oral cavity	OSCC	sulfur compound metabolic process	168/7305	339/18723	4.50e-05	3.84e-04	168
GO:00160537	Oral cavity	OSCC	organic acid biosynthetic process	155/7305	316/18723	1.64e-04	1.13e-03	155
GO:00463947	Oral cavity	OSCC	carboxylic acid biosynthetic process	154/7305	314/18723	1.73e-04	1.19e-03	154
GO:00100015	Oral cavity	OSCC	glial cell differentiation	110/7305	225/18723	1.56e-03	7.45e-03	110
GO:00219158	Oral cavity	OSCC	neural tube development	77/7305	152/18723	2.26e-03	1.00e-02	77
GO:00086524	Oral cavity	OSCC	cellular amino acid biosynthetic process	42/7305	76/18723	2.93e-03	1.27e-02	42
GO:19016074	Oral cavity	OSCC	alpha-amino acid biosynthetic process	37/7305	68/18723	7.09e-03	2.63e-02	37

Page: 1 2 3 4 5

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0120023	Esophagus	ESCC	Carbon metabolism	79/4205	115/8465	2.50e-05	1.21e-04	6.22e-05	79
hsa0123023	Esophagus	ESCC	Biosynthesis of amino acids	49/4205	75/8465	4.35e-03	1.12e-02	5.74e-03	49
hsa0120033	Esophagus	ESCC	Carbon metabolism	79/4205	115/8465	2.50e-05	1.21e-04	6.22e-05	79
hsa0123033	Esophagus	ESCC	Biosynthesis of amino acids	49/4205	75/8465	4.35e-03	1.12e-02	5.74e-03	49
hsa0120021	Liver	Cirrhotic	Carbon metabolism	64/2530	115/8465	6.37e-09	1.18e-07	7.26e-08	64
hsa00270	Liver	Cirrhotic	Cysteine and methionine metabolism	27/2530	52/8465	6.98e-04	4.15e-03	2.56e-03	27
hsa00260	Liver	Cirrhotic	Glycine, serine and threonine metabolism	22/2530	40/8465	7.85e-04	4.51e-03	2.78e-03	22
hsa012304	Liver	Cirrhotic	Biosynthesis of amino acids	35/2530	75/8465	1.54e-03	7.83e-03	4.83e-03	35
hsa0120031	Liver	Cirrhotic	Carbon metabolism	64/2530	115/8465	6.37e-09	1.18e-07	7.26e-08	64
hsa002701	Liver	Cirrhotic	Cysteine and methionine metabolism	27/2530	52/8465	6.98e-04	4.15e-03	2.56e-03	27
hsa002601	Liver	Cirrhotic	Glycine, serine and threonine metabolism	22/2530	40/8465	7.85e-04	4.51e-03	2.78e-03	22
hsa0123011	Liver	Cirrhotic	Biosynthesis of amino acids	35/2530	75/8465	1.54e-03	7.83e-03	4.83e-03	35
hsa0120041	Liver	HCC	Carbon metabolism	89/4020	115/8465	3.92e-11	6.56e-10	3.65e-10	89
hsa0123021	Liver	HCC	Biosynthesis of amino acids	53/4020	75/8465	3.79e-05	2.11e-04	1.18e-04	53
hsa002702	Liver	HCC	Cysteine and methionine metabolism	35/4020	52/8465	3.03e-03	9.94e-03	5.53e-03	35
hsa002602	Liver	HCC	Glycine, serine and threonine metabolism	28/4020	40/8465	3.28e-03	1.07e-02	5.93e-03	28
hsa0120051	Liver	HCC	Carbon metabolism	89/4020	115/8465	3.92e-11	6.56e-10	3.65e-10	89
hsa0123031	Liver	HCC	Biosynthesis of amino acids	53/4020	75/8465	3.79e-05	2.11e-04	1.18e-04	53
hsa002703	Liver	HCC	Cysteine and methionine metabolism	35/4020	52/8465	3.03e-03	9.94e-03	5.53e-03	35
hsa002603	Liver	HCC	Glycine, serine and threonine metabolism	28/4020	40/8465	3.28e-03	1.07e-02	5.93e-03	28

Page: 1 2

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

PHGDH

insertion

In_Frame_Ins

novel

c.51_52insCGTAACTTTCCAAGTCTG

p.Pro17_Cys18insArgAsnPheProSerLeu

p.P17_C18insRNFPSL

O43175

protein_coding

TCGA-A8-A06P-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Unspecific

PHGDH

insertion

Nonsense_Mutation

novel

c.882_883insATAATCCCCACAGTAATGTTATGAGGGAGATAGGATCAACCCA

p.Cys295IlefsTer8

p.C295Ifs*8

O43175

protein_coding

TCGA-A8-A07J-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

5-fluorouracil

PHGDH

insertion

Nonsense_Mutation

novel

c.80_81insATTTTCTTTTTGATAGTCGAATTCCCTTCAACGTCTA

p.Leu28PhefsTer4

p.L28Ffs*4

O43175

protein_coding

TCGA-A8-A08H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

PHGDH

SNV

Missense_Mutation

novel

c.686N>C

p.Val229Ala

p.V229A

O43175

protein_coding

deleterious(0)

probably_damaging(0.98)

TCGA-AA-3811-01

Colorectum

colon adenocarcinoma

Female

>=65

III/IV

Unknown

PHGDH

SNV

Missense_Mutation

c.1162G>A

p.Val388Met

p.V388M

O43175

protein_coding

tolerated(0.11)

benign(0.071)

TCGA-AA-A022-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

PHGDH

deletion

Frame_Shift_Del

novel

c.654delN

p.Asn218LysfsTer15

p.N218Kfs*15

O43175

protein_coding

TCGA-AY-4070-01

Colorectum

colon adenocarcinoma

Female

<65

III/IV

Chemotherapy

5-fu

PHGDH

SNV

Missense_Mutation

novel

c.625N>A

p.Leu209Ile

p.L209I

O43175

protein_coding

deleterious(0)

probably_damaging(0.992)

TCGA-A5-A0G2-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Unknown

PHGDH

SNV

Missense_Mutation

novel

c.764N>T

p.Ala255Val

p.A255V

O43175

protein_coding

deleterious(0.01)

possibly_damaging(0.611)

TCGA-A5-A0G2-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Unknown

PHGDH

SNV

Missense_Mutation

rs200693896

c.1450N>T

p.Leu484Phe

p.L484F

O43175

protein_coding

tolerated(0.06)

possibly_damaging(0.799)

TCGA-A5-A0GP-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

PHGDH

SNV

Missense_Mutation

rs142988234

c.262N>A

p.Ala88Thr

p.A88T

O43175

protein_coding

deleterious(0.02)

probably_damaging(0.997)

TCGA-A5-A1OK-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

taxol

Page: 1 2 3 4 5

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1